Skip to main content

Table 1 Regimen of chemotherapy in triple-negative breast cancers

From: Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67

Adjuvant chemotherapy regimen

Number of patients

Anthracyclin-base

60

fluorouracil+epirubicin+cyclophosphamide (FEC)

34

epirubicin+cyclophosphamide (EC)

12

adriamycin+cyclophosphamide (AC)

11

cyclophosphamide+adriamycin+fluorouracil (CAF)

3

non-Anthracyclin-base

78

tegafur-uracil (UFT)

61

cyclophosphamide+methotorexate+fluorouracil (CMF)

10

doxifluridine (5'DFUR)

4

fluorouracil (5FU)

3